ArticleScientific reports2019
Tissue-specific genes as an underutilized resource in drug discovery.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genome-wide meta-analysis of myasthenia gravis uncovers new loci and provides insights into polygenic prediction.Nature communications · 2024Pooled it
- Across species identification of genes bridging neurological and reproductive functions in mammals.iScience · 2026Article
- Integrative proteogenomic analyses identify plasma proteins that impact the risk of ischemic stroke.Communications medicine · 2026Article
- The gene expression landscape of disease genes.Genome biology · 2026Article
- GTEx pro enables accurate multi-tissue gene expression analysis using robust normalization and batch correction.Scientific reports · 2025Article
- Genes, guts, and microbes: decoding host-driven microbial regulation using intestine-specific conditional knockouts.Frontiers in immunology · 2025Review
- GETdb: A comprehensive database for genetic and evolutionary features of drug targets.Computational and structural biotechnology journal · 2024Article
- Expression patterns of housekeeping genes and tissue-specific genes in black goats across multiple tissues.Scientific reports · 2024Article
- Comparative proteomic profiling of the ovine and human PBMC inflammatory response.Scientific reports · 2024Article
- Overview of the Knowledge Management Center for Illuminating the Druggable Genome.Drug discovery today · 2024Review
- Article
- Transcriptomic analysis reveals a tissue-specific loss of identity during ageing and cancer.BMC genomics · 2023Article
- Comprehensive Analysis of Ubiquitously Expressed Genes in Humans from A Data-driven Perspective.Genomics, proteomics & bioinformatics · 2023Article
- Molecular Landscape of Tourette's Disorder.International journal of molecular sciences · 2023Article
- Transcriptome innovations in primates revealed by single-molecule long-read sequencing.Genome research · 2022Article
- Characterization of the Secretome, Transcriptome, and Proteome of Human β Cell Line EndoC-βH1.Molecular & cellular proteomics : MCP · 2022Article
- CoMI: consensus mutual information for tissue-specific gene signatures.BMC bioinformatics · 2022Article
- Considerations and challenges for sex-aware drug repurposing.Biology of sex differences · 2022Review
- BrainBase: a curated knowledgebase for brain diseases.Nucleic acids research · 2022Article
- Transcriptome analysis reveals high tumor heterogeneity with respect to re-activation of stemness and proliferation programs.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tissue-specific genes are believed to be good drug targets due to improved safety. Here we show that this intuitive notion is not reflected in phase 1 and 2 clinical trials, despite the historic success of tissue-specific targets and their 2.3-fold overrepresentation among targets of marketed non-oncology drugs. We compare properties of tissue-specific genes and drug targets. We show that tissue-specificity of the target may also be related to efficacy of the drug. The relationship may be indirect (enrichment in Mendelian disease and PTVesc genes) or direct (elevated betweenness centrality scores for tissue-specifically produced enzymes and secreted proteins). Reduced evolutionary conservation of tissue-specific genes may represent a bottleneck for drug projects, prompting development of novel models with smaller evolutionary gap to humans. We show that the opportunities to identify tissue-specific drug targets are not exhausted and discuss potential use cases for tissue-specific genes in drug research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.